Virtual Care in Canada: progress and potential. Report of the Virtual Care Task Force
https://policybase.cma.ca/link/policy14470

POLICY TYPE
Policy endorsement

DATE
2022-02-26

TOPICS
Health information and e-health

Documents
Digital Health Care and Competition – a perspective from The Canadian Medical Association
https://policybase.cma.ca/link/policy14444

POLICY TYPE
Parliamentary submission

DATE
2021-06-25

TOPICS
Health information and e-health

Documents
Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Enhancing equitable access to virtual care in Canada: Principle-based recommendations for equity
https://policybase.cma.ca/link/policy14447

POLICY TYPE  Policy endorsement
DATE  2021-04-30
TOPICS  Population health, health equity, public health
        Health information and e-health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Pre-budget Submission
https://policybase.cma.ca/link/policy14259

POLICY TYPE
Parliamentary submission

DATE
2020-08-07

TOPICS
- Physician practice, compensation, forms
- Health information and e-health
- Health care and patient safety
- Health systems, system funding and performance

Documents
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy1514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Guiding principles for the optimal use of data analytics by physicians at the point of care

https://policybase.cma.ca/link/policy11812

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2016-02-27
TOPICS  Health information and e-health

Documents
# Report of the Virtual Care Task Force

[https://policybase.cma.ca/link/policy14440](https://policybase.cma.ca/link/policy14440)

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Policy endorsement</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2020-02-29</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health information and e-health</td>
</tr>
</tbody>
</table>

## Documents

[Virtual Care Recommendations for Scaling Up Virtual Medical Services](https://policybase.cma.ca/link/policy14440)
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Principles concerning physician information
https://policybase.cma.ca/link/policy208

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2002-06-02
TOPICS  Health information and e-health
         Ethics and medical professionalism

Documents

Putting Patients First : Comments on Bill C 6 (Personal Information Protection and Electronic Documents Act) : Submission to the Senate Standing Committee on Social Affairs, Science and Technology
https://policybase.cma.ca/link/policy1979

POLICY TYPE  Parliamentary submission
LAST REVIEWED  2019-03-03
DATE  1999-11-25
TOPICS  Ethics and medical professionalism
         Health care and patient safety
         Health information and e-health

Documents
“Putting Patients First”

Comments on Bill C-6
(Personal Information Protection and Electronic Documents Act)

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

Nov 27, 1999
Claire O’Grady
Peer Medical, Inc.
600-1010 Richmond St.,
Toronto, Ont., M5X 2Z5

Executive Summary

The Canadian Medical Association is concerned that the present draft of Bill C-6, the Personal Information Protection and Electronic Documents Act, which is currently before the Senate Standing Committee on Social Affairs, Science and Technology, does not provide adequate protection of personal information. The bill would grant significant power to the federal government to regulate the collection, use, and disclosure of personal information.

The bill is too vague and lacks specific provisions that would ensure the protection of personal information. It is important to ensure that personal information is protected from unauthorized access, use, or disclosure.

The CMA recommends that the bill be amended to include specific provisions that would ensure the protection of personal information. The bill should also be amended to include provisions that would ensure that personal information is not used for purposes that are not justified.

The CMA is encouraged to provide feedback to the Senate Standing Committee on Social Affairs, Science and Technology on the draft bill before it is passed into law.

Claire O’Grady
Peer Medical, Inc.
600-1010 Richmond St.,
Toronto, Ont., M5X 2Z5

November 27, 1999

Canadian Medical Association
701-730 Bay St.
Toronto, Ont., M5G 0C8

Pamela McNamee, Executive Director, Policy


p. 12
“Listening to our Patient’s Concerns”
Comments on Bill C-54 (Personal Information Protection and Electronic Document Act)
Submission to the House of Commons Standing Committee on Industry

March 18, 1999

Columbia, Ont.

Health care and patient safety
Health information and e-health
Ethics and medical professionalism
Guiding Principles for Physician Electronic Medical Records (EMR) Adoption in Ambulatory Clinical Practice

https://policybase.cma.ca/link/policy9117

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2008-02-23
TOPICS  Health information and e-health
Cannabis for Medical Purposes

CMA POLICY

http://policybase.cma.ca/link/policy10045

POLICY TYPE Policy document
LAST REVIEWED 2019-03-03
DATE 2010-12-04
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Cannabis for Medical Purposes

The Canadian Medical Association (CMA) has long recognized the varied requirements of those individuals suffering from terminal illness or chronic diseases for which conventional treatments are not effective and for whom cannabidiol (CBD) is a possibility.

There has been a growing awareness of the issues related to the local and national public health and safety implications of using cannabis for medical purposes. The CMA was one of the first national medical organizations to support research into uses of cannabis and has been advocating for the development of evidence-based policies on the use of cannabis for pain relief.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.

This CMA policy document highlights the following recommendations:

1. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
2. Support the development of evidence-based policies on the use of cannabis for pain relief, including its impact on public health and safety.
3. Increase support for the development of scientific knowledge about the medical use of cannabis for pain relief, including its effectiveness in reducing pain and its impact on patients' quality of life.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2011-05-28
REPLACES  Medication use and seniors
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association
https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE: Response to consultation
DATE: 2019-02-20
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
         Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
        Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE  2018-10-02
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA submission:
IMPLEMENTATION OF NATIONAL PHARMACARE

Submission to the Advisory Council
November 2018